Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Prokinetic effects of the neurokinin NK2 receptor agonist [Lys5,MeLeu9,Nle10]-NKA(4-10) on bladder and colorectal activity in minipigs.

Rupniak NMJ, Katofiasc MA, Marson L, Ricca DJ, Thor KB, Burgard EC.

Neuropeptides. 2019 Oct;77:101956. doi: 10.1016/j.npep.2019.101956. Epub 2019 Jul 11.

PMID:
31324387
2.

Affinity, potency, efficacy, and selectivity of neurokinin A analogs at human recombinant NK2 and NK1 receptors.

Rupniak NMJ, Perdona E, Griffante C, Cavallini P, Sava A, Ricca DJ, Thor KB, Burgard EC, Corsi M.

PLoS One. 2018 Oct 25;13(10):e0205894. doi: 10.1371/journal.pone.0205894. eCollection 2018.

3.

Colorectal and cardiovascular effects of [Lys5,MeLeu9,Nle10]-NKA(4-10) in anesthetized macaques.

Rupniak NMJ, Katofiasc M, Burgard EC, Thor KB.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Sep;391(9):907-914. doi: 10.1007/s00210-018-1520-6. Epub 2018 Jun 1.

PMID:
29858647
4.

[Lys5,MeLeu9,Nle10]-NKA(4-10) Elicits NK2 Receptor-Mediated Micturition and Defecation, and NK1 Receptor-Mediated Emesis and Hypotension, in Conscious Dogs.

Rupniak NMJ, Katofiasc M, Walz A, Thor KB, Burgard EC.

J Pharmacol Exp Ther. 2018 Jul;366(1):136-144. doi: 10.1124/jpet.118.248765. Epub 2018 May 4.

PMID:
29728445
5.

Prokinetic effects of neurokinin-2 receptor agonists on the bladder and rectum of rats with acute spinal cord transection.

Marson L, Thor KB, Katofiasc M, Burgard EC, Rupniak NMJ.

Eur J Pharmacol. 2018 Jan 15;819:261-269. doi: 10.1016/j.ejphar.2017.12.017. Epub 2017 Dec 10.

6.

Maintenance of bladder innervation in diabetes: a stereological study of streptozotocin-treated female rats.

Langdale CL, Thor KB, Marson L, Burgard EC.

Auton Neurosci. 2014 Oct;185:59-66. doi: 10.1016/j.autneu.2014.06.007. Epub 2014 Jul 1.

PMID:
25066250
7.

Effects of the 5-HT4 receptor agonist, cisapride, on neuronally evoked responses in human bladder, urethra, and ileum.

Kullmann FA, Kurihara R, Ye L, Wells GI, McKenna DG, Burgard EC, Thor KB.

Auton Neurosci. 2013 Jun;176(1-2):70-7. doi: 10.1016/j.autneu.2013.02.020. Epub 2013 Mar 17.

PMID:
23511063
8.

Synaptic activation of bulbospongiosus motoneurons via dorsal gray commissural inputs.

Best TK, Marson L, Thor KB, Burgard EC.

J Neurophysiol. 2013 Jan;109(1):58-67. doi: 10.1152/jn.00752.2012. Epub 2012 Oct 17.

9.

Properties of urethral rhabdosphincter motoneurons and their regulation by noradrenaline.

Yashiro K, Thor KB, Burgard EC.

J Physiol. 2010 Dec 15;588(Pt 24):4951-67. doi: 10.1113/jphysiol.2010.197319. Epub 2010 Oct 25.

10.

A positive modulator of K Ca 2 and K Ca 3 channels, 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591), inhibits bladder afferent firing in vitro and bladder overactivity in vivo.

Hougaard C, Fraser MO, Chien C, Bookout A, Katofiasc M, Jensen BS, Rode F, Bitsch-Nørhave J, Teuber L, Thor KB, Strøbaek D, Burgard EC, Rønn LC.

J Pharmacol Exp Ther. 2009 Jan;328(1):28-39. doi: 10.1124/jpet.108.143123. Epub 2008 Sep 26.

PMID:
18820135
11.

New pharmacological treatments for urinary incontinence and overactive bladder.

Burgard EC, Fraser MO, Karicheti V, Ricca DJ, Thor KB.

Curr Opin Investig Drugs. 2005 Jan;6(1):81-9. Review.

PMID:
15675607
12.

Serotonergic modulation of bladder afferent pathways.

Burgard EC, Fraser MO, Thor KB.

Urology. 2003 Oct;62(4 Suppl 1):10-5. Review.

PMID:
14550832
13.

2', 3'-O-(2,4,6,trinitrophenyl)-ATP and A-317491 are competitive antagonists at a slowly desensitizing chimeric human P2X3 receptor.

Neelands TR, Burgard EC, Uchic ME, McDonald HA, Niforatos W, Faltynek CR, Lynch KJ, Jarvis MF.

Br J Pharmacol. 2003 Sep;140(1):202-10. Epub 2003 Jul 29.

14.

Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM.

McGaraughty S, Chu KL, Bitner RS, Martino B, El Kouhen R, Han P, Nikkel AL, Burgard EC, Faltynek CR, Jarvis MF.

J Neurophysiol. 2003 Oct;90(4):2702-10. Epub 2003 Jun 18.

15.

A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat.

Jarvis MF, Burgard EC, McGaraughty S, Honore P, Lynch K, Brennan TJ, Subieta A, Van Biesen T, Cartmell J, Bianchi B, Niforatos W, Kage K, Yu H, Mikusa J, Wismer CT, Zhu CZ, Chu K, Lee CH, Stewart AO, Polakowski J, Cox BF, Kowaluk E, Williams M, Sullivan J, Faltynek C.

Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17179-84. Epub 2002 Dec 13.

16.

Antagonism of P2X3-containing channels: commentary on Spelta et al.

Jarvis MF, Burgard EC.

Br J Pharmacol. 2002 Mar;135(6):1343-4. No abstract available.

17.

Potent desensitization of human P2X3 receptors by diadenosine polyphosphates.

McDonald HA, Chu KL, Bianchi BR, McKenna DG, Briggs CA, Burgard EC, Lynch KJ, Faltynek C, Cartmell J, Jarvis MF.

Eur J Pharmacol. 2002 Jan 25;435(2-3):135-42.

PMID:
11821019
18.

Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the P2X(3) allosteric modulator, cibacron blue.

Jarvis MF, Wismer CT, Schweitzer E, Yu H, van Biesen T, Lynch KJ, Burgard EC, Kowaluk EA.

Br J Pharmacol. 2001 Jan;132(1):259-69.

19.

Competitive antagonism of recombinant P2X(2/3) receptors by 2', 3'-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate (TNP-ATP).

Burgard EC, Niforatos W, van Biesen T, Lynch KJ, Kage KL, Touma E, Kowaluk EA, Jarvis MF.

Mol Pharmacol. 2000 Dec;58(6):1502-10.

PMID:
11093790
20.

Channel properties determine the transient activation kinetics of recombinant GABA(A) receptors.

Burgard EC, Haas KF, Macdonald RL.

Brain Res Mol Brain Res. 1999 Nov 10;73(1-2):28-36.

PMID:
10581395
21.

Molecular and functional characterization of human P2X(2) receptors.

Lynch KJ, Touma E, Niforatos W, Kage KL, Burgard EC, van Biesen T, Kowaluk EA, Jarvis MF.

Mol Pharmacol. 1999 Dec;56(6):1171-81.

PMID:
10570044
22.

Allosteric modulation and accelerated resensitization of human P2X(3) receptors by cibacron blue.

Alexander K, Niforatos W, Bianchi B, Burgard EC, Lynch KJ, Kowaluk EA, Jarvis MF, van Biesen T.

J Pharmacol Exp Ther. 1999 Dec;291(3):1135-42.

PMID:
10565834
23.

P2X receptor-mediated ionic currents in dorsal root ganglion neurons.

Burgard EC, Niforatos W, van Biesen T, Lynch KJ, Touma E, Metzger RE, Kowaluk EA, Jarvis MF.

J Neurophysiol. 1999 Sep;82(3):1590-8.

24.

Pharmacological characterization of recombinant human and rat P2X receptor subtypes.

Bianchi BR, Lynch KJ, Touma E, Niforatos W, Burgard EC, Alexander KM, Park HS, Yu H, Metzger R, Kowaluk E, Jarvis MF, van Biesen T.

Eur J Pharmacol. 1999 Jul 2;376(1-2):127-38.

PMID:
10440098
25.

Expression of functional GABAA receptors in transfected L929 cells isolated by immunomagnetic bead separation.

Greenfield LJ Jr, Sun F, Neelands TR, Burgard EC, Donnelly JL, MacDonald RL.

Neuropharmacology. 1997 Jan;36(1):63-73.

PMID:
9144642
26.

Properties of recombinant gamma-aminobutyric acid A receptor isoforms containing the alpha 5 subunit subtype.

Burgard EC, Tietz EI, Neelands TR, Macdonald RL.

Mol Pharmacol. 1996 Jul;50(1):119-27.

PMID:
8700104
27.

NMDA and non-NMDA synaptic currents in rat neocortex during early postnatal development.

Hablitz JJ, Burgard EC.

Epilepsy Res Suppl. 1996;12:45-52. No abstract available.

PMID:
9302502
28.

N-methyl-D-aspartate receptor-mediated calcium accumulation in neocortical neurons.

Burgard EC, Hablitz JJ.

Neuroscience. 1995 Nov;69(2):351-62.

PMID:
8552233
29.

Developmental changes in the voltage-dependence of neocortical NMDA responses.

Burgard EC, Hablitz JJ.

Brain Res Dev Brain Res. 1994 Jul 15;80(1-2):275-8.

PMID:
7955353
30.
31.
32.

Developmental changes in NMDA and non-NMDA receptor-mediated synaptic potentials in rat neocortex.

Burgard EC, Hablitz JJ.

J Neurophysiol. 1993 Jan;69(1):230-40.

PMID:
8094431
34.
35.
36.

Long-term potentiation: studies in the hippocampal slice.

Sarvey JM, Burgard EC, Decker G.

J Neurosci Methods. 1989 May;28(1-2):109-24. Review.

PMID:
2542698
37.

Supplemental Content

Loading ...
Support Center